DDrare: Database of Drug Development for Rare Diseases

Cc-5013 (DrugBank: -)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
28	全身性アミロイドーシス	2
96	クローン病	1

28. 全身性アミロイドーシス　［臨床試験数：212，薬物数：234（DrugBank：72），標的遺伝子数：54，標的パスウェイ数：170］

Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

2 / 212 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00166413 (ClinicalTrials.gov)	April 2005	12/9/2005	Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis	A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis	Amyloidosis	Drug: CC-5013	Mayo Clinic	NULL	Completed	18 Years	N/A	Both	38	Phase 2	United States
2	NCT00091260 (ClinicalTrials.gov)	January 2004	7/9/2004	CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis	Multiple Myeloma	Drug: dexamethasone;Drug: lenalidomide	Vaishali Sanchorawala	Celgene Corporation	Completed	18 Years	N/A	All	82	Phase 2	United States

96. クローン病　［臨床試験数：2,209，薬物数：1,276（DrugBank：240），標的遺伝子数：166，標的パスウェイ数：210］

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00446433 (ClinicalTrials.gov)	March 2002	7/3/2007	A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease	A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease	Crohn's Disease	Drug: CC-5013	Celgene Corporation	NULL	Completed	12 Years	75 Years	Both	90	Phase 2	United States;France;Israel;United Kingdom